Finland· FI-REL-REL3790

Cea-Scan

A 99mtc-technetium-anticarcinoembryoantigen-antikörper product containing arcitumomab, registered in Finland by Immunomedics GmbH.

ATC V09IA01

Checked against Fimea (Finland) on

Informational only — not a medical device.

SOURCE REGISTER · FIFimea (Finland)normalisedCea-ScanATCV09IA01REGISTER NO.FI-REL-REL3790PACKS LISTED0CHECKEDSeptember 27, 2026

The record

At a glance

Fimea (Finland)
Active substance
Arcitumomab
Manufacturer
Immunomedics GmbH
Country
Finland (FI)
ATC code
V09IA01
ATC class
99mTc-Technetium-Anticarcinoembryoantigen-Antikörper
Reimbursed
Not published by this register
Source register
Fimea (Finland)
Last checked
September 27, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/faf0e4d5-b421-43da-9786-aafee8144ec9
GET /v1/drugs/faf0e4d5-b421-43da-9786-aafee8144ec9?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "ddd": null,
  "form": "injektiokuiva-aine, liuosta varten",
  "route": null,
  "ddd_unit": null,
  "strength": "1.25 mg",
  "atc_label": "teknetium(99mTc)anti(CEA) vasta-aine",
  "ma_number": null,
  "auth_status": "Myyntilupa peruuntunut",
  "eu_ma_number": "EU/1/96/023/001",
  "fimea_rel_id": "REL3790",
  "authorised_at": "1996-10-04"
}

See everything about 99mtc-technetium-anticarcinoembryoantigen-antikörper.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.